

O INITIAL - Complete sections 1 - 4

SPECIAL AUTHORITY REQUEST LUSPATERCEPT

RENEWAL - Complete sections 1 - 3, and 5

HLTH 5827 2023/06/21

For u	p-to-date criteria and fo	rms, please c	heck: <u>www.gov.bc.ca/pharmacarespe</u>	cialauthor	ity	If v	ou have received this fax in error, please write	
This fa		leged and conta	nail requests to: PharmaCare, Box 9652 Strains confidential information intended only fo			MIS	DOI NOVE RECEIVED AIRS IAS IN HEROIT, piezes write SDIRECTED across the front of the form and fax -1-free to 1-800-609-4884, then destroy the pages eived in error.	
			est, approval is granted solely for the purpose					
			quested medication is, or is not, suitable for ar			Pharma	aCare will be unable to return a response.	
. 0	5 With miormation missin	ig will be retu	incu for completion. If no presenter fu	X OI III GIIII	g uuuress is proviucu,		reare will be unable to return a response.	
	TION 1 – HEMATOL	OGIST INF	FORMATION	SECTION	ON 2 – PATIENT I	NFOR	MATION	
Nam	e and Mailing Address			Patient ((Family) Name			
			Patient (Given) Name(s)					
Call	ID / ONLY C. II ID) In	Dhara Namahan (in dada ana arada)	Data of	D:::::	١	Date of Application (VVVV / AAAA / DD)	
Colle	ege ID (use ONLY College ID	number)	Phone Number (include area code)	Date of	Birth (YYYY / MM / DD))	Date of Application (YYYY / MM / DD)	
	TIGAL TOD A	Hematologis	t's Fax Number	60.716		Person	al Health Number (PHN)	
	ITICAL FOR A MELY RESPONSE				CAL FOR ->			
SEC	TION 3 – MEDICAT	ION REQU	ESTED AND PATIENT WEIGH	T (must l	be requested by	a hem	atologist)	
	UCDATEDCEDT							
	USPATERCEPT 5 mg and 75 mg vials for su	bcutaneous in	iection				9901-0421	
			,					
			A maximum of 1.25 mg/kg (up to 120 r				proved for eligible patients.	
C	urrent Weight:	(kg)	Please use the appropriate combination	n of strengt	hs of vials to minimize w	astage.		
SEC	TION 4 – CRITERIA	FOR INITI	AL COVERAGE: 6 MONTHS					
Apı	proval subject to ALL of t	he criteria bel	ow being met (mark boxes and comple	ete blanks a	as applicable)			
A.	Confirmed diagnosis	of transfusion	dependent anemia associated with beta	thalaccomic	a in an adult nationt			
A.	_		•		•	tmont	ith lucratorcant AND	
☐ The patient has been receiving regular transfusions: 6-20 RBC units in the 24 weeks prior to initiating treatment with luspatercept A☐ During this time, the patient has not had a transfusion-free period greater than 35 days						ith luspatercept AND		
	Please note: Luspatercept is not eligible for PharmaCare coverage for the treatment of myelodysplastic syndrome.							
B. Number of RBC units tranfused over the preceding 24 weeks:								
			eek Date Range (YYYY/MM/DD) – (YYYY/MI	M/DD)	Number of RBC Units			
	Due liverenterent							
	Pre-luspatercept		to		/ 24 weeks	5		
SEC	TION 5 - CRITERIA	FOR RENE	WAL: 6 MONTHS					
Apı	proval subject to ALL of t	he criteria bel	ow being met (mark boxes and comple	ete blanks a	as applicable)			
	Attain and maintain a mir	imum 220/2 rov	duction in transfusion burden (number o	f DDC units	war the most represent	ativo 12	week period from within the 6 months	
	Attain and maintain a minimum 33% reduction in transfusion burden (number of RBC units over the most representative 12 week period from within the 6 months immediately preceding this request) when compared to the pre-treatment baseline RBC transfusion burden (measured over the 24 weeks prior to initiating treatment							
	with luspatercept). PharmaCare will calculate the average number of RBC units/week to assess the percentage reduction in transfusion burden.							
		1	2 Week Date Range (YYYY/MM/DD) – (YYY	Y/MM/DD)	Number of RBC U	nits		
	Most remark to the			, 20,	Tamber of fibe o			
	Most representative 12 week period from wi	thin						
	the preceding 6 months		to		/ 12 w	eeks		

LUSPATERCEPT

Patient (Family) Name	Patient (Given) Name(s)	Personal Health Number (PHN)			
SECTION 6 – ADDITIONAL COMMENTS					
Report all adverse events to the post-market survei	llance program, Canadian Vigilaı	nce, toll-free 1-866-234-2345 (health professionals only).			
Personal information on this form is collected under the authority of, a		sed with the patient that the purpose of releasing their			
with, the British Columbia Pharmaceutical Services Act 22(1) and Freedon Protection of Privacy Act 26 (a),(c),(e). The information is being collected		o PharmaCare is to obtain Special Authority for prescription			
of (a) administering the PharmaCare program, (b) analyzing, planning	and evaluating the	coverage and for the purposes set out here.			
Special Authority and other Ministry programs and (c) to manage and system generally. If you have any questions about the collection of this					
Health Insurance BC from Vancouver at 1-604-683-7151 or from elsewl	ere in BC toll free at				
1-800-663-7100 and ask to consult a pharmacist concerning the Specia	nematologist sig	Hematologist Signature (Mandatory)			

EFFECTIVE DATE (YYYY / MM / DD)

DURATION OF APPROVAL

including any annual deductible requirement, and to any other applicable PharmaCare pricing policy.

PHARMACARE USE ONLY

STATUS